Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Cross Below Two Hundred Day Moving Average – Should You Sell?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shares passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $67.83 and traded as low as $66.85. Tarsus Pharmaceuticals shares last traded at $67.52, with a volume of 1,715,283 shares changing hands.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 63.9% to about $194.5 million, with record sales of XDEMVY. Tarsus expects $715 million–$730 million in XDEMVY sales for 2026, supporting the growth outlook. Article: Tarsus expects $715M-$730M 2026 XDEMVY sales
• Positive Sentiment: Analysts raised price targets and maintained bullish ratings: Guggenheim lifted its target to $97 with a Buy rating, while Oppenheimer raised its target to $103 and kept an Outperform rating. Guggenheim rating Oppenheimer price target
• Neutral Sentiment: Management plans to participate in upcoming investor conferences; this may provide opportunities to discuss the business and outlook, but no new financial information was announced. Tarsus investor conference announcement
• Negative Sentiment: The quarterly net loss widened to $668 million, primarily due to acquisition-related costs, despite revenue growth. Tarsus also deferred European and Japanese filing plans, delaying potential international expansion. Q3 loss and XDEMVY sales Sales outlook and international filing plans

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Guggenheim raised their price target on shares of Tarsus Pharmaceuticals from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Finally, The Goldman Sachs Group began coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $116.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.57.

Tarsus Pharmaceuticals Trading Down 2.2%

The company has a current ratio of 1.96, a quick ratio of 3.17 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average of $75.06 and a 200 day moving average of $67.83. The company has a market cap of $3.33 billion, a P/E ratio of -4.45 and a beta of 0.34.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). The business had revenue of $194.57 million during the quarter, compared to the consensus estimate of $187.83 million. Tarsus Pharmaceuticals had a negative return on equity of 24.51% and a negative net margin of 102.93%. On average, analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Bobak R. Azamian sold 10,000 shares of Tarsus Pharmaceuticals stock in a transaction on Friday, September 4th. The shares were sold at an average price of $90.56, for a total value of $905,600.00. Following the completion of the sale, the chief executive officer owned 827,991 shares in the company, valued at $74,982,864.96. The trade was a 1.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the completion of the sale, the director owned 94,487 shares of the company’s stock, valued at $7,405,891.06. This represents a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 48,031 shares of company stock worth $4,004,227. Corporate insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently bought and sold shares of TARS. Parallel Advisors LLC increased its stake in Tarsus Pharmaceuticals by 139.2% in the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after purchasing an additional 291 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Tarsus Pharmaceuticals by 851.6% during the third quarter. Farther Finance Advisors LLC now owns 590 shares of the company’s stock valued at $46,000 after purchasing an additional 528 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 367.1% during the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock valued at $50,000 after purchasing an additional 558 shares during the period. Covestor Ltd raised its holdings in shares of Tarsus Pharmaceuticals by 40.0% during the third quarter. Covestor Ltd now owns 1,095 shares of the company’s stock valued at $86,000 after purchasing an additional 313 shares during the period. Finally, State of Wyoming bought a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth about $103,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.